Intraoperative infusion of noradrenaline improves platelet aggregation in patients undergoing coronary artery bypass

Sukhi Singh1, Tor Damén2,3, Mikael Dellborg1

  • 1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Insights

Low-dose noradrenaline infusion improved platelet function and clot formation in patients undergoing cardiac surgery. This strategy may help reduce bleeding complications in patients on antiplatelet therapy.

Area of Science:

  • Cardiovascular Surgery
  • Anesthesiology
  • Hematology

Background:

  • Bleeding complications are a significant concern during cardiac surgery.
  • New strategies are needed to optimize hemostasis in these patients.
  • Platelet dysfunction can exacerbate bleeding, especially in patients on antiplatelet therapy.

Purpose of the Study:

  • To investigate the effect of noradrenaline (NA) infusion on platelet aggregation and clot formation.
  • To assess if NA can enhance platelet function in patients undergoing coronary artery bypass grafting (CABG).
  • To evaluate NA as a potential method to improve intraoperative hemostasis.

Main Methods:

  • A prospective parallel-group randomized study involving 24 CABG patients.
  • Patients received standard care or standard care plus continuous low-dose noradrenaline infusion.
  • Platelet aggregation and clot formation were measured using aggregometry and thromboelastometry before and after anesthesia induction.

Main Results:

  • Noradrenaline infusion significantly improved adenosine diphosphate (ADP)- and arachidonic acid (AA)-induced platelet aggregation.
  • Maximum clot firmness (INTEM) increased in the noradrenaline group compared to the control group.
  • Low-dose noradrenaline enhanced platelet reactivity and clot firmness in patients treated with acetylsalicylic acid (ASA).

Conclusions:

  • Continuous low-dose noradrenaline infusion enhances platelet aggregation and clot firmness in CABG patients.
  • Noradrenaline may be a valuable tool to acutely improve platelet function during cardiac surgery.
  • This approach offers a potential strategy to mitigate bleeding risks in patients on antiplatelet therapy.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
420
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
249
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
364
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
663
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K